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Abstract. Background: Antimicrobial-resistant (AMR) gonorrhoea is a global public health threat. Discriminatory
point-of-care tests (POCT) to detect drug sensitivity are under development, enabling individualised resistance-guided
therapy. Methods: An individual-based dynamic transmission model of gonorrhoea infection in MSM living in London
has been developed, incorporating ciproﬂoxacin-sensitive and resistant strains. The time-dependent sexual contact
network is captured by periodically restructuring active connections to reﬂect the transience of contacts. Different
strategies to improve treatment selection were explored, including discriminatory POCT and selecting partner treatment
based on either the index case or partner susceptibility. Outcomes included population prevalence of gonorrhoea and drug
dose counts. Results: It is shown that using POCT to detect ciproﬂoxacin-sensitive infections could result in a large
decrease in ceftriaxone doses (by 70% compared with the reference case in the simulations of this study). It also suggests
that ceftriaxone use can be reduced with existing technologies, albeit to a lesser degree; either using index case sensitivity
proﬁles to direct treatment of partners, or testing notiﬁed partners with strain discriminatory laboratory tests before
treatment, reduced ceftriaxone use in our model (by 27% and 47% respectively). Conclusions: POCT to detect
ciproﬂoxacin-sensitive gonorrhoea are likely to dramatically reduce reliance on ceftriaxone, but requires the
implementation of new technology. In the meantime, the proportion of unnecessary ceftriaxone treatment by testing
partners before treatment could be reduced signiﬁcantly. Alternatively, index case sensitivity proﬁles could be used to
select effective treatments for partners.
Additional keywords: antimicrobial resistance, diagnostics, gonorrhoea, point-of-care test, resistance-guided therapy.
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Introduction
Gonorrhoea is caused by infection with the Gram-negative
bacterium, Neisseria gonorrhoeae. Urethral infection in men
commonly causes discharge (>80%) and dysuria (>50%), with
an onset period of 2–5 days after exposure.1 Complications
arising from gonorrhoea include epididymo-orchitis, prostatitis,
conjunctivitis, arthritis, pelvic inﬂammatory disease, chronic
pelvic pain, ectopic pregnancy and tubal factor infertility.1,2
Diagnoses of gonorrhoea in England increased from 14 985 in
2008, to 44 676 cases in 2017, of which nearly half were
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reported in men who have sex with men (MSM).3 MSM bear a
disproportionate burden of sexually transmissible infections
(STIs).4,5 Gonorrhoea is on the World Health Organization
(WHO) high-priority list, requiring immediate action due to
concern about the spread of antimicrobial-resistant (AMR)
strains and the prospect of untreatable, multi-drug-resistant
gonorrhoea.6,7 Currently, N. gonorrhoeae has developed
resistance to all major classes of antibiotics.8
AMR gonorrhoea strains have been reported since the early
1940s; by the end of the decade, over 90% of treatments with
sulfonamides failed in vitro.8–10 In England, the Gonococcal
Resistance to Antimicrobials Surveillance Program (GRASP)
has reported on microbiological resistance in gonorrhoea since
2000. In 2004, GRASP reported increased N. gonorrhoeae
resistance to ciproﬂoxacin (14.1%),11 resulting in a change in
UK guidelines, to extended spectrum cephalosporins
(ceﬁxime).12 Subsequently, increasing ceﬁxime resistance led
to another guideline change in 2011, to combination therapy;
injectable ceftriaxone with oral azithromycin.2 Most recently
in 2019, due to concerns about azithromycin resistance,
the guidelines have been further updated to recommend 1 g
ceftriaxone or 500 mg ciproﬂoxacin, if susceptibility is known
(https://www.bashhguidelines.org/current-guidelines/urethritis-
and-cervicitis/gonorrhoea-2019/). Despite the changes to ﬁrst-line
treatment recommendations, resistance to previously used
drugs has remained high and stable; for example, ciproﬂoxacin
(36.4%) and tetracycline (43.7%), although resistance to
penicillin has slowly decreased from a peak of 17.1% in 2014
to 10.8% in 2017.13 Interestingly, ceﬁxime resistance increased
and then decreased, which may suggest a ﬁtness cost of
resistance.13,14
The current situation is therefore that our ﬁrst-line antibiotic
therapy (ceftriaxone) is also the last line. In 2014, the
world’s ﬁrst documented treatment failure to dual
ceftriaxone–azithromycin therapy was reported in England,15
with increasing reports of cases in 2018.6,16–18 There is an
urgent need, therefore, to develop new diagnostics and
treatment strategies in order to preserve ceftriaxone efﬁcacy
and to slow or reduce the spread of antibiotic-resistant strains.19
Given the available susceptibility data, it is clear that many
infections could be treated with previous antibiotics; ~90%with
penicillin alone.13 However, it is essential that alternative
treatments are accurately targeted to prevent treatment
failure, preserve efﬁcacy of last-line antibiotics and reduce
the selection pressure for resistance.
Utilising point-of-care tests (POCT) was identiﬁed as a key
priority for controlling curable STIs in the review by
O’Neill.17,19,20 POCT is any method that can be used to
provide accurate and rapid diagnostics, informing treatment
within a single clinical visit. A previous modelling paper
demonstrated that POCT with lower sensitivity and speciﬁcity
could be cost-effective in controlling STIs if they could be
produced at low enough cost, which may be especially
relevant in low-income settings to support shifting away from
current syndromic management approaches.21 A systematic
review of current developments in POCT for STIs has recently
beenconducted,22and it is likely thatPOCTwill becomeavailable
that can detect and differentiate resistant gonorrhoea strains and/
or susceptibility to alternative antibiotic treatments.
Mathematical modelling allows for the testing of possible
interventions in public health systems before they are applied in
reality, and given a sufﬁciently detailed and well-calibrated
model, enables comparison of the beneﬁts of different possible
intervention strategies.23 We have previously developed a
static model to evaluate the cost-effectiveness of POCT and
POCT AMR tests for gonorrhoea,20,24,25 but a key limitation
was the lack of infection dynamics to evaluate the effect of
interventions at the population level and to predict gonorrhoea
incidence over time. Published models of gonorrhoea include
ordinary differential equation approaches, which are fast,
require only a small number of parameters and are easy to
analyse. However, they assume a well-mixed population, and
fail to model the true structure of sexual partnership
networks.26,27 Alternative approaches include individual-
based models that are typically computationally intensive,
require large numbers of parameters and repeated
simulations.28–30 The key advantage compared with static or
ordinary equation models is that individual-level effects such
as contact tracing, partner notiﬁcation or testing of targeted
index-linked treatment choices or interventions can be
straightforwardly included, and the model can be extended
without altering the underlying contact structures and
dynamics. Individual-based models can be used as an
additional tool for evaluation of longer-term dynamic
effects of both POCT, vaccination or novel drug
treatments,31–34 and this paper adds another tool.
In this study, we report the development of a novel
individual-based model, with multiple strain transmission
dynamics across a hybrid static-dynamic sexual contact
network. The model reproduces key epidemiological details
of MSM gonorrhoea infection, such as low prevalence and
reinfection, while retaining observed features of the contact
network topology over extended time periods. It allows a
ﬂexible choice of complex (individual-based) treatment,
testing and tracing options, including strain-sensitive
diagnostic tests with variable time delays, which we use to
evaluate the effect of a range of novel control strategies.
Methods
Model overview
We developed a stochastic, discrete-time Markov model,
which describes individual-level gonorrhoea transmission,
treatment and recovery (illustrated schematically in Fig. 1),
within a time-varying sexual partnership network. Two
independent strains are considered, which can be treated
with two different drug therapies, ciproﬂoxacin (Cipr) or
ceftriaxone (Ceft). The strains differ only in their response
to treatment: one (non-AMR) strain is susceptible to both drug
therapies, while the other (AMR) strain is susceptible to Ceft
but resistant to Cipr. Recovery from either infection may be
spontaneous (natural recovery) or through treatment. As
individuals show negligible immunity to re-infection, and
remain susceptible to further infections, the model of each
individual’s infection status is of susceptible-infected-
susceptible (SIS) type.26 Treatment may be sought by
individuals with symptomatic infections, prescribed through
partner notiﬁcation (tracing), patient recall following routine
(asymptomatic) screening or misdiagnosis revealed by
laboratory testing. The model includes ﬂexible combinations
of diagnosis and treatment scenarios, summarised in
Table 1 and is described in the outline below. Three patient
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groups are considered, as outlined in Figure 1, deﬁned
as: Symptomatic patients (diagnosed based on clinical
presentation); Asymptomatic infections (diagnosed based
on laboratory tests); and Traced contacts (presumptive
treatment).
Full details of the model, its implementation and calibration
using data on gonorrhoea in MSM living in London, and the
resulting values of epidemiological parameters, are presented in
the Supplementary Material. The simulation code is available
online: https://data.bris.ac.uk/data/dataset/3erdo698eboli2ptxi
324rsuhg.
Scenario analysis
The diagnosis and treatment scenarios we consider are designed
to assess the effect (on infection prevalence and the volume
and efﬁcacy of drug choice) of POCT and other informed
treatment strategies. We compare a baseline reference
scenario with additional scenarios divided into three
categories: (1) Undirected drug choice; (2) Individualised
treatment; and (3) Pretreatment testing.
Undirected drug choice – treatment not always according to
guidelines, but not based on any additional diagnostic
information (probabilistic adherence to guidelines).
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Fig. 1. Schematic overview of patient pathways: (a) current management and (b) discriminatory antimicrobial resistant (AMR) point-of-care
tests (POCT). Individuals can attend a clinic either due to symptoms, routine asymptomatic testing or partner tracing. Symptomatic individuals
typically have a swab sent for microbiological testing (AMR phenotype testing) at the same time as a polymerase chain reaction (PCR; nucleic
acid ampliﬁcation (NAAT)) test is performed, whereas for asymptomatic individuals, only a PCR test is done, with a swab taken if diagnosis is
conﬁrmed. Contacts may have any combination of PCR test, AMR phenotype testing or no test. (a) Under current patient pathways for
gonorrhoea, all infections are treated with ceftriaxone. (b) Under AMR POCT treatment decision is based on the result of the test.
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Individualised treatment – treatment decision is based on
diagnostic test results, either from a discriminatory POCT
(same day) or using current laboratory microbiological
susceptibility test results (~2 weeks).
Pretreatment testing – treatment is only given once a
diagnostic test has been performed (either POCT or
laboratory nucleic acid ampliﬁcation test (NAAT)). For
symptomatic and asymptomatic patients, treatment may then
be based on current guidelines or individualised based on results
of susceptibility testing of an individual’s infection (laboratory
or POCT). For traced contacts, the treatment decision can be
based on guidelines or on the microbiological test results of the
index case.
Baseline situation
The reference scenario (REF) is based on current gonorrhoea
treatment guidelines, in which there is 100% adherence to Ceft
as the ﬁrst-line treatment. Treatment is given to all individuals,
who either present with a symptomatic infection, attend a clinic
after recall following testing or are traced through a treated
partner.
The reference scenario is calibrated (see Supplementary
Material) to equilibrate on endemic prevalence and incidence
appropriate for an MSM population similar to that of London;
prevalence of ~4% (equally divided between AMR and non-
AMR strains), and approximately ﬁve positive diagnoses
per day per 10 000 individuals. A recent analysis of MSM in
London found the self-reported gonorrhoea diagnosis in the
last year to be 5.2% (Gay Mens Survey) and national Public
Health England (PHE) data report high rates of gonorrhoea
diagnoses in MSM in London.33,34
Comparison scenarios
Scenario 1, undirected drug choice, attempts to reﬂect the reality
of current UK prescribing, where less than 100% Ceft usage has
been reported.13
We consider two options as counterfactuals to evaluate the
effect of lower than 100% adherence to recommended
guidelines such that some infections (with an AMR strain)
are not cured. Here, we assume that drug treatment is
assigned in an undirected manner, with Ceft or Cipr
treatment given in the absence of knowledge of strain
phenotype, with ﬁxed probability. Two ﬁxed ratios are
considered: (1a) 86% Ceft and 14% Cipr (in accordance with
ﬁndings of the GRASP 2014 report); or (1b) equal likelihood of
Ceft and Cipr.
Scenario 2, individualised treatment, simulates the effect of
two different possible methods to incorporate strain
phenotyping into drug choice. (2a) An idealised (100%
accurate) POCT that identiﬁes, on the day of clinic
attendance, whether an individual is infected with
gonorrhoea, in a non-discriminatory manner. (2b) Ideal
Table 1. Testing and treatment scenarios. The options for treatment are ceftriaxone (Ceft) (according to UK guidelines 2018) or ciproﬂoxacin (Cipr)
N/A, not applicable; POCT, point-of-care test; AMR, antimicrobial resistance; NAAT, nucleic acid ampliﬁcation test
Scenario Who is treated Information for decision Treatments
REF Reference
N/A Symptomatic patients, Asymptomatic
infections and Traced contacts
Treat as per guidelines 100% Ceft
1 Undirected drug choice
1a 86% : 14% All diagnosed infections and Traced contacts Guidelines (86% adherence) 86% Ceft, 14% Cipr
1b 50% : 50% All diagnosed infections and Traced contacts Guidelines (50% adherence) 50% Ceft, 50% Cipr
2 Individualised treatment
2a POCT Diagnosed infections only Guidelines 100% Ceft
2b Discriminatory AMR
POCT
Diagnosed infections only POCT AMR Ceft or Cipr
2c Informed treatment
(recalled)
Symptomatic patients and Traced contacts Guidelines Ceft
Asymptomatic infections Microbiological testing Ceft or Cipr
2d Informed treatment
(recalled + traced)
Symptomatic patients Guidelines Ceft
Asymptomatic infections Microbiological testing Ceft or Cipr
Traced contacts Index case microbiology Ceft or Cipr
3 Pretreatment testing
3a Pretreatment testing
(traced)
Symptomatic patients and Asymptomatic
infections
Guidelines Ceft
Traced contacts (infected only) Guidelines (NAAT test before
treatment)
Ceft
3b Pretreatment test (all) Symptomatic patients, Asymptomatic
infections and Traced contacts
Guidelines (NAAT test before
treatment)
Ceft
3c Pretreatment test
(asymptomatic and
traced)
Symptomatic patients Guidelines Ceft
Asymptomatic infections Microbiological testing Ceft or Cipr
Traced contacts Microbiological testing Ceft or Cipr
3d Pretreatment test (all) Symptomatic patients, Asymptomatic
infections and Traced contacts
Microbiological testing Ceft or Cipr
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scenario of AMR POCT, where the strain is also identiﬁed. The
prescription decision follows accordingly: Ceft is prescribed
only to infected individuals (2a) or the strain-appropriate choice
of Ceft or Cipr (2b). The second approach is to use an
‘informed’ prescription decision based on strain phenotypic
data obtained through laboratory testing, either for individuals
recalled for treatment as a result of prior testing (2c), or
additionally for those traced through partner notiﬁcation (2d),
using the phenotype of the index patient to inform the treatment
choice of their traced partners.
Scenario 3 adds ‘pretreatment testing’ to previous scenarios:
individuals attending for treatment are tested for infection
before any prescription decision is made. The pathway by
which individuals receive treatment becomes the same as
those attending via standard asymptomatic testing, thus
accruing additional delay due to laboratory test and patient
recall delays. The aim is to address treatment wastage due to, for
example, treating traced contacts who are assumed to be
infected regardless of whether they show symptoms; (3a)
pretreatment testing is applied to traced partners of index
cases; (3b) pretreatment testing of all individuals, whether
traced or treatment-seeking due to symptoms. In reality, it
would be highly unusual for clinicians to await test results
before treating a patient with obvious symptoms; however, this
scenario provides a comparison that can highlight potential
sources of treatment wastage. As per the reference scenario,
treatments for (3a) and (3b) are exclusively treated with Ceft.
Finally, in scenarios (3c) and (3d), informed discriminatory
treatment is included as per scenarios (2c) and (2d), with
additional pretreatment testing according to (3a) and (3b)
above. In these scenarios, we therefore allow treatment with
Cipr as an alternative to Ceft, depending on strain
discriminatory testing results.
Experimental procedure and outputs
Simulations for each treatment scenario include an equilibration
period (10 000 days) in which transmission dynamics and
treatment protocols are ﬁxed according to the reference
scenario. This ensures that strain prevalence and incidence
settle on stable target values, and are sufﬁciently transmitted
to and distributed within the contact network (10 000
individuals). After the equilibration period, a new scenario is
activated, modifying the relevant model treatment pathways as
described above.
We collect outputs after one (simulated) year, to make
comparisons between different scenarios. Speciﬁcally, we
analyse disease prevalence and incidence – both by strain,
and overall – and drug dosages – both total prescription
counts, and sub-divided by efﬁcacy. There are four efﬁcacy
categories: optimal treatment (Ceft when an individual was
infected with the AMR strain, or Cipr if infected only with the
non-AMR strain), over-treatment (Ceftwhen infected only with
the non-AMR strain), under-treatment (Ciprwhen infected with
the AMR strain) and wasted treatment (either drug prescribed in
the absence of infection).
To obtain robust statistics from the inherently stochastic
transmission processes, 500 realisations of each scenario were
simulated, each with different partnership network dynamics
and initial infection states.
Results
The data shown in Fig. 2 summarise the key outcomes of
simulations given the treatment scenarios described above
(summarised in Table 1), 1 year after having switched from
the reference scenario (REF). Figure 2a provides the treatment
breakdown in terms of the number of doses of each drug
prescribed and their efﬁcacy depending on the different
infection states of individuals. In Figure 2b we report the
change in strain prevalence over the course of the same year.
Reference scenario
Simulating the model as per the REF scenario with 100%
exclusive Ceft treatment for an additional year after the
nominal equilibration period yields the following annual
statistics, providing a baseline for comparison with
alternative strategies: 4.2% overall prevalence (AMR strain:
2.18%, non-AMR only: 2.04%, co-infected: 0.16%) and 1977
per 10 000 individual doses of Ceft. Of these doses, 31.0% were
optimally prescribed, while the remaining 69.0% comprised
27.8% over-treatments (individuals with no AMR infection
component) and 41.2% ‘wasted’ (individuals treated but not
infected with either strain).
Scenario 1: undirected drug choice
Undirected drug choice leads to an increase in the overall
dosing by 6.3% (scenario 1a) and 51.2% (1b) above the
reference value. While there is a reduction in the number of
Ceft doses in both scenarios, of 8.6% (1a) and 24.3% (1b), the
number of suboptimal doses were both greater than in the
reference scenario (1424 doses (1a) and 2096 doses (1b) per
10 000 individuals).
Undirected drug choice leads to new optimal and suboptimal
treatments compared with the reference scenario; in the former
case, individuals treated with Cipr who were infected only with
the susceptible strain, and in the latter, treatment failures for
individuals treated with Cipr who were infected with the
resistant strain. Under-treatment comprised 4.7% of doses in
scenario (1a) and 21.2% in scenario (1b).
Undirected treatment also affects strain prevalence. While
the overall prevalence (infections with either strain) increased
only by a small margin – 0.6% (1a) and 2.3% (1b) – individual
strain prevalence diverged signiﬁcantly. In particular, the AMR
strain prevalence increased by 3.8% (1a) and 20.6% (1b), with
corresponding decreases in the susceptible strain prevalence of
2.8% (1a) and 17.3% (1b).
Scenario 2: individualised treatment
POCT (scenarios 2a, 2b) represents an ideal regime of
individualised treatment, and has signiﬁcant beneﬁts in all
measures that we consider.
Non-discriminatory POCT (2a) leads to a 42.7% decrease in
the overall number of doses with respect to the reference
scenario (both Ceft prescription only). Optimal doses
accounted for 51.6% of the total, with the remaining doses
all over-treatments, as expected. Instant positivity testing
reduces the proportion of wasted doses to zero. The overall
infection prevalence also decreased, by 9.1%, with a 9.5%
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reduction in the AMR strain prevalence, and 8.6% reduction in
individuals with susceptible-only infections.
Discriminatory POCT (2b) leads to the same total number of
doses as the non-discriminatory test, but the ability to prescribe
Cipr leads to a large decrease (of 69.8%) in the number of Ceft
doses. As each detected strain is treated with the correct drug, a
100% optimal dose ratio is achieved, with no under/over-
treatments or wasted doses; strain discrimination shifts over-
treatments in scenario (2a) to optimal treatments (with Cipr) in
scenario (2b). The overall infection prevalences are broadly
similar to those for scenario (2a).
In contrast to POCT, informed treatment choice (scenarios
2c, 2d) seeks to individualise treatment as currently achievable,
via (strain discriminatory) laboratory testing for screened
individuals (2c) and additionally for those identiﬁed via
contact tracing (2d), using the phenotype of the index
patient. Both improve drug usage, with respect to the
reference scenario. When applied to screened patients (2c),
there is an 0.8% decrease in total doses, of which 91.4% were
Ceft, representing a 9.3% decrease with respect to the reference
scenario, but there remained a signiﬁcant proportion of over-
treated (19.9%) and wasted doses (41.3%). Extending informed
choice to secondary cases identiﬁed via partner notiﬁcation
(2d), the total number of doses is similar to the reference
scenario, but there is a signiﬁcant reduction in the number of
Ceft doses (by 27.2%), an increase in optimal doses, fewer over-
treatments and similar wastage. The overall prevalence, both
overall and per strain, are very similar to the reference scenario
in both informed choice scenarios.
Overall, both informed choice scenarios (2c, 2d) represent an
improvement in drug usage, compared with the reference
scenario, with a higher proportion of optimal treatments and
many fewer under-treatments.
Scenario 3: pretreatment testing
Pretreatment testing seeks to address treatment wastage by
testing groups of treatment-seeking individuals before making a
prescription decision. Two scenarios (3a and 3b) apply this to
Ceft-only prescribing by testing traced partners before treatment
(3a), or testing all individuals before treatment (3b), while a
further two scenarios (3c and 3d) extend the informed choice
scenarios (2c and 2d) with additional pretreatment testing, as in
scenarios 3a and 3b respectively. The results of all four
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Fig. 2. Comparison of treatment outcomes for different diagnostic and treatment strategies over 1 year, after switching
from the reference scenario, in terms of (a) numbers of drug doses administered and (b) percentage change in gonorrhoea
prevalence. Both panels compare the treatment strategies summarised in Table 1. (a) Bar pairs report the number of doses of
ceftriaxone (Ceft; left) and ciproﬂoxacin (Cipr; right) per 10 000 individuals, over 1 year, for each treatment scenario (labels
below). Each bar is partitioned by the proportion of each prescription, which resulted in: (green) optimal treatment; that is,
Ceft when an individual had a Cipr resistant component, or Cipr if infected only with a susceptible strain; (blue) over-
treatment, where Ceft was used when no antimicrobial resistant (AMR) strain was present; (yellow) under-treatment, where
Cipr was prescribed to an individual with the AMR strain; and (red) wasted treatment, where an individual was treated with
either drug despite not being infected with gonorrhoea. Central stems and circles indicate the total numbers of (black) doses
overall, and (red) suboptimal doses – under-treated, over-treated or wasted – for both drugs together. (b) Percentage change
in prevalence compared with the reference scenario, over 1 year, in terms of individuals who are infected with either strain
(black squares), a resistant strain component (red circles) or with only the Cipr susceptible strain (blue triangles). Value
labels below indicate the absolute prevalence of gonorrhoea (either strain) after 1 year, and in parentheses, the increase or
decrease in number of new infections per 10 000 over 1 year compared with the reference scenario.
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scenarios show a signiﬁcant improvement in drug usage,
approaching the level of POCT, but at the cost of increased
prevalence (due to the delays in treatment leading to increased
duration of infection).
In the Ceft-only pretreatment testing scenarios, the total
number of doses was reduced by ~35% (both 3a and 3d)
compared with the reference scenario, accompanied by
increases of 55% (3a) and 60% (3b) in the proportion
of optimal treatments. While a signiﬁcant proportion of
prescriptions were over-treatments (3a: 44.1%, 3b: 43.3%),
there was a substantial reduction in wasted treatments, to
~8.1% (3a) and 7.4% (3b) compared with over 41% at
reference. The negligible difference between these reductions
suggests that wastage in the reference scenario is primarily due
to treating uninfected traced partners. However, the additional
delays due to pretreatment screening lead to increases in
prevalence, of 4.7% (3a) and 25.8% (3b).
Scenarios (3c) and (3d) reduce total drug usage by similar
levels to scenarios (3a) and (3b), but with improved dose
optimality because Cipr can be prescribed. In scenario (3c),
65.0% of prescriptions are optimal, with Ceft usage reduced by
47.5% with respect to the reference scenario. Over-treatments
(26.6%) still occur, as symptomatic treatment-seekers do not
receive individualised treatments, but under-treatment with
Cipr (0.2%) is rare – representing those individuals who are
infected with an AMR strain discordantly with their partner. In
scenario (3d), individualised treatment is available to all
individuals, leading to a very high dose optimality (91.5%),
almost complete elimination of under-treatment and large
reduction in the use of Ceft (by 64.3%) compared with the
reference scenario; a similar dosing pattern to the
discriminatory POCT. The majority of suboptimal drug use
is wasted treatment, caused by natural recovery during the test
and recall delay. While the laboratory testing delay has beneﬁts
in reducing drug use, it also leads to increased gonorrhoea
prevalence, to ~4.4% in scenarios 3a and 3c, and to ~5.3% in
scenarios 3b and 3c, rises of 4% and 25% with respect to the
reference scenario.
Discussion
We have considered the potential effect of current and near
future diagnostic test technologies (laboratory and POCT) on
the management and control of gonorrhoea in an exemplar high-
risk population in a UK city (MSM in London). Point-of-care
tests, which do not identify AMR, could still have an important
role in reducing unnecessary antibiotic prescriptions (i.e. of
uninfected contacts), but POCT AMR would be the ideal
situation that could not only reduce prescription of
ceftriaxone, but also potentially reduce prevalence due to
reductions in treatment delays (mainly for asymptomatic
patients). Some improvements could be made using current
data by informing treatment of contacts based on the index
susceptibility proﬁle. The technical and informatics challenges
of this may outweigh potential gains, given that same-day
testing is already available in some clinics (e.g. Dean St
Express clinic), and that POCT tests are available and POCT
AMR tests are likely to be available within a few years.
Conversely, given the current ﬁnancial climate and cuts to
sexual health services, it may be prudent to try to optimise
the use of current susceptibility test data, as large scale
investment in new testing technology and service
reorganisation or modernisation may not be ﬁnancially viable.
This study makes available a ﬂexible, individual-based
stochastic network simulation model, calibrated to reproduce
the transmission dynamics of gonorrhoea in a population of
MSM in London. Notably, we developed an efﬁcient algorithm
to reproduce heterogeneous patterns of breaking and forming
partnerships between individuals while retaining the longer-
term cumulative degree distribution. We then used this
model framework to explore potential interventions such as
POCT or phenotypic resistance proﬁling, which could enable
individually tailored antibiotic usage and control antibiotic
resistant gonorrhoea. As for all mathematical models, results
are dependent on both modelling assumptions and on
parametrisation; while we have used epidemiologically
plausible parameter values, the conclusions below use
quantitative results from the model to identify qualitative
differences between model scenarios.
We found that, compared with the reference scenario
(assuming that 50% of infections are resistant to
ciproﬂoxacin), discriminatory POCT, which detect genetic
resistance markers could both reduce the use of ceftriaxone
(by 70%) and reduce overall gonorrhoea prevalence by
reducing current delays in treatment of asymptomatic
infections. Antibiotic-resistant gonorrhoea is a serious public
health threat6–8 and notably the review by O’Neill called for
rapid roll-out of rapid diagnostic tests to detect resistance and
direct treatment.19 Most highly resistant organisms occur in the
context of hospital settings and clinically unwell patients;
however, gonorrhoea is mostly diagnosed in outpatient,
community and online testing settings; often patients are
asymptomatic and infections are non-lethal and largely
curable. These considerations make it less likely that expensive
diagnostics will be considered cost-effective for STI clinics,
which are already being asked to make signiﬁcant cost-
savings, and even less likely in low-income settings.19,30
However, the use of POCT to reduce clinic attendances and
reduce time-to-treatment could be cost-effective even without
consideration of AMR.20
We also considered the potential effect of treating
individuals, attending clinics as a result of partner
notiﬁcation, with antibiotics, as determined by the resistance
proﬁle of the index case (directed treatment). This strategy was
found to reduce prescriptions of ceftriaxone by 27%. The
effectiveness of this strategy depends on the delays assumed
between index and partner treatment, but might be feasible in at
least a proportion of cases. Crucially, neither AMR POCT nor
index-directed partner treatment resulted in a relative increase
in resistant strains of AMR gonorrhoea. We also estimated that
~40% of treatments are given to individuals who are not actually
infected. This is in line with previous static analyses,19,20,25
which suggested that POCT would reduce over-treatment,
although its relevance to preventing emergence and spread of
resistance is not fully understood.
Antibiotic stewardship encourages the use of appropriate
antibiotics by using the right antibiotic, at the right dose, for the
right duration and at the right time (https://www.cdc.gov/
Antimicrobial-resistant Neisseria gonorrhoea Sexual Health G
antibiotic-use/stewardship-report/improving-antibiotic-use.
html). We identiﬁed potential antibiotic wastage due to treating
traced partners who are uninfected. Pre-testing symptomatic
patients to determine antibiotic susceptibility before treatment
is not advised due to introducing unnecessary treatment delays
and consequent increase in prevalence. It may be possible,
however, with current technology to introduce individualised
treatment for asymptomatic patients or traced contacts
(microbiological susceptibility testing of index cases) if
suitable information systems can be put in place to link
patient records to the results of susceptibility testing (either
their own or the index case), together with appropriate follow up
of cases.
The key strengths of this study are that we used a hybrid
static-dynamic network model, which has the ﬂexibility to be
extended in several ways without signiﬁcantly increasing model
run time, including: alternative network structures; increasing
number of strains; increased complexity of infection process
within individuals, taking into account HIV status; vaccination
status or multiple anatomical sites of infection. There are
limitations to our analysis; we have assumed in the ﬁrst
instance that strains are at equilibrium (50/50) before the
introduction of an intervention and are identical except in
response to antibiotic treatment. For simplicity, we also
assume that all strains remain 100% susceptible to the last-
line drug, ceftriaxone. This is reasonable to explore the relative
effects of different interventions, but could form the subject of
further investigation. We do not consider any explicit de novo
evolution of new resistance or decreasing susceptibility to
antibiotic treatment, although there is potential for
individual-level variation in treatment response due to the
model structure chosen. Further, we have not accounted for
variability in epidemiological parameters such as
transmissibility or duration either due to biological variability
in strains or behavioural differences due to condom use or
treatment-seeking behaviours. We have included asymptomatic
and symptomatic infections with corresponding differences in
treatment-seeking behaviour and hence duration of infection.
In summary, POCT to detect ciproﬂoxacin-sensitive
gonorrhoea infection could contribute to reduced reliance on
ceftriaxone. We could signiﬁcantly reduce the proportion of
unnecessary ceftriaxone treatments by testing partners before
treatment, and use existing phenotype data more informatively.
For example, if laboratory turnaround times are fast enough,
index case sensitivity proﬁles could be used to select effective
treatments for partners. Future work should prioritise further
modelling, attempting to recapture time series and explicit
models of resistance evolution. There is also a need to
estimate the costs and timeframe of emergence of new
resistant strains of gonorrhoea.
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